EUVIMEDEUVIMED entdecken
Vergleichsstudie

Addition of Cladribine to Idarubicin and Cytarabine during Induction Increases the Overall Efficacy Rate in Adult Patients with Acute Myeloid Leukemia: A Matched-Pair Retrospective Comparison

Yaoyao Shen, Jia Chen, Yuejun Liu, Depei Wu

Chemotherapy · 2014 · 60 (5-6) · 368-374

DOI: 10.1159/000440943 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Chemotherapy, online erschienen am 24.10.2015. Verfasst von Yaoyao Shen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, and Collaborative Innovation Center of Hematology, Soochow Univ…. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The aims of this study were to evaluate a novel induction regimen composed of idarubicin (IDA), cytarabine (Ara-C) and cladribine (IAC regimen) for acute myeloid leukemia (AML) patients, and to identify the prognostic factors affecting treatment outcomes.

Methods

The clinical data of 27 untreated AML patients who received the IAC regimen as primary induction therapy in our hospital between April and November 2014 were analyzed retrospectively. The treatment outcomes of the IAC regimen were compared with two IA (IDA + Ara-C) regimens (IDA 10 mg/m2 and IDA 12 mg/m2) in a pair-matched analysis.

Results

The complete remission (CR) rate in the IAC arm was higher compared to the IAL arm (p = 0.002) as was the overall efficacy rate (p = 0.017). There was no significant difference in outcomes between the IAC and IAH (Ara-C with high-dose IDA) arms. The IAC arm contained significantly higher CR rates than the IAL (Ara-C with low-dose IDA) arm in both the intermediate group (p = 0.050) and the unfavorable group (p = 0.013). Toxicity did not differ between the IAC group and the other two arms. High WBC at diagnosis (p = 0.022) and an unfavorable karyotype (p = 0.026) were related to a poorer response. The IAC regimen (p = 0.013) had greater superiority over the IAL regimen on efficacy than over the IAH regimen (p = 0.041).

Conclusions

The IAC regimen achieved a more significant advantage over the IAL regimen without increasing the risk of adverse events. The efficacy of induction therapy is associated with WBC at diagnosis, karyotype and induction regimen.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsCladribineCytarabineDrug SynergismFemaleHumansIdarubicinLeukemia, Myeloid, AcuteMaleMiddle AgedRemission InductionRetrospective StudiesTreatment OutcomeYoung Adult

Substanzen

CytarabineCladribineIdarubicin

Autor:innen und Institutionen

  • Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, and Collaborative Innovation Center of Hematology, Soochow University, and Suzhou Institute of Blood and Marrow Transplantation, and…

Zitieren

APA

Shen, Y., Chen, J., Liu, Y., & Wu, D. (2014). Addition of Cladribine to Idarubicin and Cytarabine during Induction Increases the Overall Efficacy Rate in Adult Patients with Acute Myeloid Leukemia: A Matched-Pair Retrospective Comparison. Chemotherapy, 60(5-6), 368-374. https://doi.org/10.1159/000440943

Vancouver

Shen Y, Chen J, Liu Y, Wu D. Addition of Cladribine to Idarubicin and Cytarabine during Induction Increases the Overall Efficacy Rate in Adult Patients with Acute Myeloid Leukemia: A Matched-Pair Retrospective Comparison. Chemotherapy. 2014;60(5-6):368-374. doi:10.1159/000440943

BibTeX
@article{Shen2014,
  author = {Shen, Yaoyao and Chen, Jia and Liu, Yuejun and Wu, Depei},
  title = {Addition of Cladribine to Idarubicin and Cytarabine during Induction Increases the Overall Efficacy Rate in Adult Patients with Acute Myeloid Leukemia: A Matched-Pair Retrospective Comparison},
  journal = {Chemotherapy},
  year = {2014},
  volume = {60},
  number = {5-6},
  pages = {368--374},
  doi = {10.1159/000440943}
}
Kostenlos starten →